An indole alkaloid from Strychnos erichsonii

Le premier alcaloïde indolique de type vobasine rencontré dans les #Loganiaceae a été isolé des écorces de #Strychnos erichsonii, récoltées en Guyane Française. Sa structure confirmée par cristallographie Rx. (Résumé d'auteur

Jet Propellant 8 versus Alternative Jet Fuels

The Air Force is the largest user of jet fuel in the Department of Defense DOD, consuming 2.4 billion gallons per year. In light of environmental impacts associated with using nonrenewable fuel sources and national security concerns regarding dependency on foreign oil, it is no surprise that the United States is paying more attention to alternative fuels. Both DOD and Air Force energy strategies address the need to develop and produce such fuels. The DOD has made a commitment to energy security, establishing an energy initiative that strives to modernize infrastructure, increase utility and energy conservation, enhance demand reduction, and improve energy flexibility, thereby saving taxpayer dollars and reducing emissions that contribute to air pollution and global climate change. This initiative has the following four goals 1. Maintain or enhance operational effectiveness while reducing total force energy demands 2. Increase energy strategic resilience by developing alternative assured fuels and energy 3. Enhance operational and business effectiveness by institutionalizing energy considerations and solutions in DoD planning business processes 4. Establish and monitor Department-wide energy metrics

Contribution of Matrix Metalloproteinase-9 to Cerebral Edema and Functional Outcome following Experimental Subarachnoid Hemorrhage

Background: Cerebral edema is an important risk factor for death and poor outcome following subarachnoid hemorrhage (SAH). However, underlying mechanisms are still poorly understood. Matrix metalloproteinase (MMP)-9 is held responsible for the degradation of microvascular basal lamina proteins leading to blood-brain barrier dysfunction and, thus, formation of vasogenic cerebral edema. The current study was conducted to clarify the role of MMP-9 for the development of cerebral edema and for functional outcome after SAH. Methods: SAH was induced in FVB/N wild-type (WT) or MMP-9 knockout (MMP-9(-/-)) mice by endovascular puncture. Intracranial pressure (ICP), regional cerebral blood flow (rCBF), and mean arterial blood pressure (MABP) were continuously monitored up to 30 min after SAH. Mortality was quantified for 7 days after SAH. In an additional series neurological function and body weight were assessed for 3 days after SAH. Subsequently, ICP and brain water content were quantified. Results: Acute ICP, rCBF, and MABP did not differ between WT and MMP-9(-/-) mice, while 7 days' mortality was lower in MMP-9(-/-) mice (p = 0.03; 20 vs. 60%). MMP-9(-/-) mice also exhibited better neurological recovery, less brain edema formation, and lower chronic ICP. Conclusions: The results of the current study suggest that MMP-9 contributes to the development of early brain damage after SAH by promoting cerebral edema formation. Hence, MMP-9 may represent a novel molecular target for the treatment of SAH. Copyright (C) 2011 S. Karger AG, Base

Effects of incidental physical activity on morphosyntactic processing in aging

Older adults have difficulties in sentence comprehension when working memory (WM) load increases (e.g., multiple embedded clauses). Structured physical activity has been related to improvements in cognition; however, incidental physical activity (PA, i.e., unstructured daily physical activities), particularly incidental vigorous activity has been poorly studied in relation to its effects on behavior. Furthermore, no positive effect on language has been reported in either form of physical activity. The aim of this study was to evaluate how two levels of PA (high or low) affect WM processing and how this, in turn, may affect morphosyntactic processing in older adults. Individuals with high PA (n = 18) had a higher WM load effect than those with low PA (n = 18), both behaviorally (greater differences between high and low WM loads in correct responses) and in terms of event-related potentials (only subjects with high PA showed LAN and P600b amplitude differences between high and low WM loads). These findings suggest that PA promotes cognitive strategies to face WM loads and morphosyntactic processing

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

BACKGROUND: Immunization of patients with Alzheimer's disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery (NTB) and a decrease in brain volume compared with placebo. METHODS: A follow-up study, Study AN1792(QS-21)-251, was conducted to assess the long-term functional, psychometric, neuroimaging, and safety outcomes of patients from the phase 2a study 4.6 years after immunization with AN1792. The results were analyzed by comparing patients originally identified as antibody responders in the AN1792 phase 2a study with placebo-treated patients. RESULTS: One hundred and fifty-nine patients/caregivers (30 placebo; 129 AN1792) participated in this follow-up study. Of the 129 AN1792-treated patients, 25 were classified in the phase 2a study as antibody responders (anti-AN1792 titers > or = 1:2,200 at any time after the first injection). Low but detectable, sustained anti-AN1792 titers were found in 17 of 19 samples obtained from patients classified as antibody responders in the phase 2a study. No detectable anti-AN1792 antibodies were found in patients not classified as antibody responders in the phase 2a study. Significantly less decline was observed on the Disability Assessment for Dementia scale among antibody responders than placebo-treated patients (p=0.015) after 4.6 years. Significant differences in favor of responders were also observed on the Dependence Scale (p=0.033). Of the small number of patients who underwent a follow-up MRI, antibody responders showed similar brain volume loss during the follow-up period subsequent to the AN1792 phase 2a study compared with placebo-treated patients. CONCLUSIONS: Approximately 4.6 years after immunization with AN1792, patients defined as responders in the phase 2a study maintained low but detectable, sustained anti-AN1792 antibody titers and demonstrated significantly reduced functional decline compared with placebo-treated patients. Brain volume loss in antibody responders was not significantly different from placebo-treated patients approximately 3.6 years from the end of the original study. No further cases of encephalitis were noted. These data support the hypothesis that Abeta immunotherapy may have long-term functional benefits

La sarcosporidiose chez le buffle africain (Syncerus caffer)

Après quelques généralités sur la sarcosporidiose, une description des kystes sarcosporidiens trouvés chez le buffle africain (S. caffer) et quelques hypothèses sur le cycle évolutif sont donnée

Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury

Objectives: To determine the neuroprotective efficacy of the inert gas xenon following traumatic brain injury and to determine whether application of xenon has a clinically relevant therapeutic time window. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57BL/6N mice (n = 196). Interventions: Seventy-five percent xenon, 50% xenon, or 30% xenon, with 25% oxygen (balance nitrogen) treatment following mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Outcome following trauma was measured using 1) functional neurologic outcome score, 2) histological measurement of contusion volume, and 3) analysis of locomotor function and gait. Our study shows that xenon treatment improves outcome following traumatic brain injury. Neurologic outcome scores were significantly (p < 0.05) better in xenon-treated groups in the early phase (24 hr) and up to 4 days after injury. Contusion volume was significantly (p < 0.05) reduced in the xenon-treated groups. Xenon treatment significantly (p < 0.05) reduced contusion volume when xenon was given 15 minutes after injury or when treatment was delayed 1 or 3 hours after injury. Neurologic outcome was significantly (p < 0.05) improved when xenon treatment was given 15 minutes or 1 hour after injury. Improvements in locomotor function (p < 0.05) were observed in the xenon-treated group, 1 month after trauma. Conclusions: These results show for the first time that xenon improves neurologic outcome and reduces contusion volume following traumatic brain injury in mice. In this model, xenon application has a therapeutic time window of up to at least 3 hours. These findings support the idea that xenon may be of benefit as a neuroprotective treatment in patients with brain trauma